Clinical trials: Chemoradiation
Cervical Cancer Screening, Gynecologic Cancers
Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer.
- Conditions
- Cervical Cancer Screening, Gynecologic Cancers, Treatment Compliance, Chemoradiotherapy
- Trial name
- NCG-Compliance (NCT07290972)
- Testing
- Not applicable- observational study
- Where
- 2 sites in India
- Volunteers
- 618 people
- Sponsor
- Tata Memorial Hospital
Rectal Cancer
BReak Interval Delayed Surgery for Gastrointestinal Extraperitoneal Rectal Cancer
This is a randomized multicentric clinical trial in patients affected by resectable rectal cancer, cT2N1-2, cT3N0-2, MRF -, aiming to evaluate the impact of the interval between chemoradiotherapy and surgery on the pathological…
- Trial name
- BRIDGE (NCT03581344)
- Testing
- Repetition of Re-staging
- Where
- Italy
- Volunteers
- 148 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Locally Advanced Rectal Cancer (LARC)
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
This is a phase II, multicenter, randomized (2:1) controlled, clinical trial to evaluate the preliminary efficacy and safety of consolidation chemotherapy (XELOX) plus dostarlimab after standard long-course CRT (ARM A) compared…
- Trial name
- IMMUNOSTAR (NCT07381777)
- Testing
- XELOX (Capecitabine and Oxaliplatin), Dostarlimab
- Where
- 30 sites in Italy
- Volunteers
- 270 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft…
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02180867
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell
Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)
To test the therapeutic ratio of accelerated radiotherapy and/or chemotherapy on locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT00563862
- Testing
- Conventional RT, Accelerated RT, Cisplatin
- Where
- 5 sites in China
- Volunteers
- 465 people
- Sponsor
- Hospital Authority, Hong Kong
Oral Cavity, Squamous Cell Carcinoma
Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients
The purpose of this study is to confirm the value of concurrent chemoradiotherapy in improving the locoregional control and survival of patients with resected locally advanced HNSCC, a phase III randomized study is proposed.
- Trial name
- NCT00201383
- Testing
- cisplatin
- Where
- Taiwan
- Volunteers
- 161 people
- Sponsor
- National Health Research Institutes, Taiwan
Small Cell Lung Cancer
Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)
This trial aims to evaluate the efficacy and safety between radiotherapy alone and concurrent chemo-radiotherapy after 3-4 cycles of chemotherapy in LS-SCLC.
- Trial name
- SCLC (NCT01745445)
- Testing
- concurrent chemo-radiotherapy arm
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00025298
- Testing
- amifostine trihydrate, carboplatin, cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Non-Small-Cell Lung
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area
- Trial name
- NCT04529564
- Where
- 12 sites in Taiwan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Esophageal Cancer
The Role of PET/MRI in Predicting the Outcome of Definitive Chemoradiotherapy for Esophageal Cancer Patients
PET/MRI has the advantage to assess the metabolism, diffusion, and perfusion parameters of the tumor simultaneously and has been investigated in some cancers with promising results.
- Trial name
- NCT05855278
- Testing
- PET/MRI
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Chang Gung Memorial Hospital
Pancreatic Cancer
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer.
- Trial name
- NCT00047710
- Testing
- Bevacizumab, Capecitabine, Radiotherapy
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00822848
- Testing
- epirubicin hydrochloride, ifosfamide, sorafenib tosylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- OHSU Knight Cancer Institute
Locally Advanced Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stability-high (MSI-H) locally advanced rectal cancer (LARC).
- Trial name
- NCT04411524
- Testing
- PD-1 antibody, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
This phase III trial is studying how well radiation therapy, amifostine, and chemotherapy work in treating young patients with newly diagnosed nasopharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage II Nasopharyngeal Undifferentiated Carcinoma AJCC v7
- Trial name
- NCT00274937
- Testing
- Amifostine, Cisplatin, Fluorouracil
- Where
- 109 sites in United States, Australia and 1 more
- Volunteers
- 111 people
- Sponsor
- Children's Oncology Group
Endometrial Cancer
Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer
Endometrial cancer is the most common gynecological malignancy affecting women's health. About 15% of the patients will have local late disease (stage III) with high risk of recurrence and tumor related mortality.
- Trial name
- NCT04453904
- Testing
- sequential radiochemotherapy in a "sanwich" mode
- Where
- China
- Volunteers
- 654 people
- Sponsor
- Peking University People's Hospital
Esophageal Cancer
PET/MRI in Predicting the Outcome of Neoadjuvant Chemoradiotherapy With Esophagectomy in Esophageal Cancer Patients
Integrated PET/MRI has the advantage to assess the metabolism, diffusion, and perfusion parameters of the tumor simultaneously. Recently, PET/MRI has been investigated in several cancers with promising results.
- Trial name
- NCT05855291
- Testing
- PET/MRI
- Where
- Taiwan
- Volunteers
- 43 people
- Sponsor
- Chang Gung Memorial Hospital
Lymphoma
Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002510
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Temple University
Diffuse Intrinsic Pontine Glioma
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with…
- Trial name
- NCT04532229
- Testing
- Nimotuzumab+CRT(concurrent IMRT and TMZ)
- Where
- 8 sites in China
- Volunteers
- 48 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Rectal Cancer Stage II, Rectal Cancer Stage III
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Rectal cancer patients who received neoadjuvant chemoradiotherapy in Peking University Third Hospital in 2021 are divided into acute myelosuppression group, chronic myelosuppression group and normal group.
- Trial name
- NCT04970498
- Testing
- MRI, blood routine test
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University Third Hospital
Ewing Sarcoma, Bone Neoplasms
Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma
This is a single-center, single-arm, prospective observational study to evaluate the long-term local control rate, safety, and efficacy of preoperative neoadjuvant radiotherapy (36-45 Gy) followed by sequential radical surgery…
- Trial name
- NCT07620431
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking University People's Hospital